Tuberculosis in an inflammatory bowel disease cohort from South Africa

BACKGROUND: Potent immunosuppressive therapy is standard treatment for inflammatory bowel disease (IBD) but carries a risk of reactivating latent tuberculosis (TB). No data exist on the burden of TB in South African patients with IBD. OBJECTIVE: To evaluate the burden of TB in IBD patients attending a large tertiary IBD clinic. METHODS: Data pertaining to patients attending the Groote Schuur Hospital IBD clinic were retrospectively analysed. Data were extracted from an existing IBD database, patient notes, the National Health Laboratory Services database and chest X-ray analysis. RESULTS: Of 614 patients, 72 (11.7%) were diagnosed with TB; 40 (55.6%) developed TB prior to the diagnosis of IBD. On regression analysis, coloured IBD patients were at increased risk for TB development (p=0.004, odds ratio (OR) 3.57, 95% confidence interval (CI) 1.49 - 8.56), as were patients with extensive Crohn's disease (CD) compared with those with less extensive disease (p=0.001, OR 2.84, 95% CI 1.27 - 6.33). No other risk factors, including the use of immunosuppressive agents, were identified for the development of TB. CONCLUSIONS: Of over 600 patients, 12% had TB either before or after IBD diagnosis. The high rate of previous TB and positive association with ethnicity probably reflect the high burden of TB in a socio-economically disadvantaged community. We recommend that IBD patients should be screened actively and monitored for TB when immunosuppressive medications are used.

Saved in:
Bibliographic Details
Main Authors: Deetlefs,E, Epstein,D, Watermeyer,G A, Seggie,R M, Thomson,S R
Format: Digital revista
Language:English
Published: South African Medical Association 2012
Online Access:http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742012001000021
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0256-95742012001000021
record_format ojs
spelling oai:scielo:S0256-957420120010000212013-01-14Tuberculosis in an inflammatory bowel disease cohort from South AfricaDeetlefs,EEpstein,DWatermeyer,G ASeggie,R MThomson,S RBACKGROUND: Potent immunosuppressive therapy is standard treatment for inflammatory bowel disease (IBD) but carries a risk of reactivating latent tuberculosis (TB). No data exist on the burden of TB in South African patients with IBD. OBJECTIVE: To evaluate the burden of TB in IBD patients attending a large tertiary IBD clinic. METHODS: Data pertaining to patients attending the Groote Schuur Hospital IBD clinic were retrospectively analysed. Data were extracted from an existing IBD database, patient notes, the National Health Laboratory Services database and chest X-ray analysis. RESULTS: Of 614 patients, 72 (11.7%) were diagnosed with TB; 40 (55.6%) developed TB prior to the diagnosis of IBD. On regression analysis, coloured IBD patients were at increased risk for TB development (p=0.004, odds ratio (OR) 3.57, 95% confidence interval (CI) 1.49 - 8.56), as were patients with extensive Crohn's disease (CD) compared with those with less extensive disease (p=0.001, OR 2.84, 95% CI 1.27 - 6.33). No other risk factors, including the use of immunosuppressive agents, were identified for the development of TB. CONCLUSIONS: Of over 600 patients, 12% had TB either before or after IBD diagnosis. The high rate of previous TB and positive association with ethnicity probably reflect the high burden of TB in a socio-economically disadvantaged community. We recommend that IBD patients should be screened actively and monitored for TB when immunosuppressive medications are used.South African Medical AssociationSAMJ: South African Medical Journal v.102 n.10 20122012-10-01journal articletext/htmlhttp://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742012001000021en
institution SCIELO
collection OJS
country Sudáfrica
countrycode ZA
component Revista
access En linea
databasecode rev-scielo-za
tag revista
region África del Sur
libraryname SciELO
language English
format Digital
author Deetlefs,E
Epstein,D
Watermeyer,G A
Seggie,R M
Thomson,S R
spellingShingle Deetlefs,E
Epstein,D
Watermeyer,G A
Seggie,R M
Thomson,S R
Tuberculosis in an inflammatory bowel disease cohort from South Africa
author_facet Deetlefs,E
Epstein,D
Watermeyer,G A
Seggie,R M
Thomson,S R
author_sort Deetlefs,E
title Tuberculosis in an inflammatory bowel disease cohort from South Africa
title_short Tuberculosis in an inflammatory bowel disease cohort from South Africa
title_full Tuberculosis in an inflammatory bowel disease cohort from South Africa
title_fullStr Tuberculosis in an inflammatory bowel disease cohort from South Africa
title_full_unstemmed Tuberculosis in an inflammatory bowel disease cohort from South Africa
title_sort tuberculosis in an inflammatory bowel disease cohort from south africa
description BACKGROUND: Potent immunosuppressive therapy is standard treatment for inflammatory bowel disease (IBD) but carries a risk of reactivating latent tuberculosis (TB). No data exist on the burden of TB in South African patients with IBD. OBJECTIVE: To evaluate the burden of TB in IBD patients attending a large tertiary IBD clinic. METHODS: Data pertaining to patients attending the Groote Schuur Hospital IBD clinic were retrospectively analysed. Data were extracted from an existing IBD database, patient notes, the National Health Laboratory Services database and chest X-ray analysis. RESULTS: Of 614 patients, 72 (11.7%) were diagnosed with TB; 40 (55.6%) developed TB prior to the diagnosis of IBD. On regression analysis, coloured IBD patients were at increased risk for TB development (p=0.004, odds ratio (OR) 3.57, 95% confidence interval (CI) 1.49 - 8.56), as were patients with extensive Crohn's disease (CD) compared with those with less extensive disease (p=0.001, OR 2.84, 95% CI 1.27 - 6.33). No other risk factors, including the use of immunosuppressive agents, were identified for the development of TB. CONCLUSIONS: Of over 600 patients, 12% had TB either before or after IBD diagnosis. The high rate of previous TB and positive association with ethnicity probably reflect the high burden of TB in a socio-economically disadvantaged community. We recommend that IBD patients should be screened actively and monitored for TB when immunosuppressive medications are used.
publisher South African Medical Association
publishDate 2012
url http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742012001000021
work_keys_str_mv AT deetlefse tuberculosisinaninflammatoryboweldiseasecohortfromsouthafrica
AT epsteind tuberculosisinaninflammatoryboweldiseasecohortfromsouthafrica
AT watermeyerga tuberculosisinaninflammatoryboweldiseasecohortfromsouthafrica
AT seggierm tuberculosisinaninflammatoryboweldiseasecohortfromsouthafrica
AT thomsonsr tuberculosisinaninflammatoryboweldiseasecohortfromsouthafrica
_version_ 1756005612259377152